Clinical Trial Update: Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders. [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 clinical trial is evaluating a combination of PD-1 inhibitors, tenofovir, chidamide, and lenalidomide in relapsed or refractory Epstein-Bar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus-associated Lymphoproliferative Disorder

Drugs mentioned

• Chidamide (chidamide)
• Lenalidomide (lenalidomide)
• Pembrolizumab (pembrolizumab)
• TENOFOVIR DISOPROXIL FUMARATE (tenofovir disoproxil fumarate)
• nivolumab (nivolumab)

Snippet

Sponsor: The Affiliated Hospital of Xuzhou Medical University | Conditions: EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING